Clinical trial · Interventional
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PRIMARY: In Phase I, to define a broadly tolerable dose of isotretinoin that can be used in combination with interferon alfa-2a (IFN alfa-2a). In Phase II, to determine trends in efficacy of isotretinoin alone or in combination with IFN alfa-2a as chemoprevention (preventing progression or recurrence) of anal intraepithelial neoplasia ( AIN ) / squamous intraepithelial lesions ( SIL ) in patients with HIV infection. SECONDARY: To evaluate the effects of isotretinoin alone or in combination with IFN alfa-2a on immune function markers, human papillomavirus (HPV) type, and HPV DNA levels. Patients with HIV infection have a significant risk of recurrence following local ablation of intraepithelial neoplasia; thus, anogenital epithelial may become an increasingly important cause of morbidity, and possibly mortality, as the HIV epidemic matures. Clinical studies of non-HIV-infected subjects have established that synthetic retinoids inhibit the progression of epithelial preneoplastic conditions and some neoplastic states.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anus Neoplasms | Anal Neoplasm | ALIAS | 0.90 |
| HIV Infections | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interferon alfa-2a | Drug | — | UNRESOLVED |
| Isotretinoin | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria Concurrent Medication: Allowed: * PCP prophylaxis (required for patients with CD4 count \< 200 cells/mm3). * Chemoprophylaxis for candidiasis and herpes simplex. * Metronidazole for up to 14 days. * Erythropoietin. Patients must have: * HIV seropositivity. * NO active opportunistic infection requiring treatment with prohibited drugs. * Phase I - Current grade 1 AIN (i.e., low grade SIL) OR treated or untreated grade 2 or 3 AIN (i.e., high grade SIL). Phase II - Prior histologically confirmed grade 2 or 3 AIN / high grade SIL, with ablative therapy within the past 30-90 days. * Capability of complying with study protocol. NOTE: * The terms condyloma, grade 1 AIN, and low grade SIL are interchangeable. Grade 2 or 3 AIN is interchangeable with high grade SIL. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active medical problems for which the patient is undergoing evaluations or for which prohibited therapy is required. * Other active malignancies requiring systemic therapy. * Significant symptomatic cardiac disease. NOTE: * Patients with malignancies being managed with local therapy (e.g., Kaposi's sarcoma, basal cell carcinoma) may enroll at the discretion of the site investigator. Concurrent Medication: Excluded: * G-CSF (filgrastim). * Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis). * Corticosteroids. * Biologic response modifiers. * Cytotoxic chemotherapy. Concurrent Treatment: Excluded: * Radiation therapy. Patients with the following prior conditions are excluded: History of ventricular arrhythmias or myocardial infarction. Prior Medication: Excluded within 20 days prior to study entry: * G-CSF (filgrastim). * Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis). * Corticosteroids. * Biologic response modifiers. * Cytotoxic chemotherapy. Prior Treatment: Excluded within 20 days prior to study entry: * Radiation therapy. Excluded within 14 days prior to study entry: * Transfusion. Active substance abuse or illegal drug use (alcohol consumption is strongly discouraged).
References
Publications (0)
Data not yet available